Patents Assigned to INATHERYS
  • Method of treating a tumor using anti-TfR antibodies
    Patent number: 12037408
    Abstract: The present invention relates to humanized antibodies that specifically hind to human transferrin receptor and their use in treating cancer and inflammatory disorders.
    Type: Grant
    Filed: December 9, 2021
    Date of Patent: July 16, 2024
    Assignee: INATHERYS
    Inventors: Pierre Launay, Coralie Belanger, Hervé Souchet
  • Anti-TfR antibodies and their use in treating proliferative and inflammatory disorders
    Patent number: 11230605
    Abstract: The present invention relates to humanized antibodies that specifically bind to human transferrin receptor and their use in treating cancer and inflammatory disorders.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: January 25, 2022
    Assignee: INATHERYS
    Inventors: Pierre Launay, Coralie Belanger, Hervé Souchet
  • USE OF THE CD71 RECEPTOR IN THE PROGNOSIS AND TREATMENT OF ENDOMETRIOSIS
    Publication number: 20190352415
    Abstract: The CD71 receptor is used as a target in the prognosis and/or treatment of endometriosis, and to a test for the prognosis or therapeutic monitoring of endometriosis, targeting this receptor.
    Type: Application
    Filed: January 19, 2018
    Publication date: November 21, 2019
    Applicants: ENDODIAG, INATHERYS
    Inventors: Pierre LAUNAY, Coralie BELANGER, Cécile REAL